2023/12/14 | Grants & Awards | Biomechanics
ValTech Lifesciences, a new venture of the ARTORG Center Cardiovascular Engineering group wins Venture Kick first stage financial and entrepreneurial support, together with five other startups. The team around co-founders are Dr. Shaokai Zheng and Prof. Dr. Dominik Obrist wants to develop a non-thrombogenic, durable heart valve prosthesis.
A large number of patients suffer from limited valve durability and the limitations of anticoagulation therapy, or from the risk of thromboembolic stroke. This is even more severe in developing or underdeveloped countries. The global market for heart valve prostheses was valued at USD 11 billion in 2021 and was estimated to reach USD 25 billion by 2030.
The team of ValTech Lifesciences are brining together state-of-the-art fluid mechanical and cardiovascular engineering research, bringing a next-generation valve design to solve the unmet clinical need. They will employ the The Venture Kick Stage I funds to accelerating the prototyping of a new non-thrombogenic, durable heart valve prosthesis.
News Venture Kick, 28 November 2023
More on the topic
Cardiovascular Engineering group